30 Day Trial

Vericel Reports Orthobiologics Growth for 4Q17, 2017

Share:

Vericel posted 4Q17 orthobiologic revenue of US $16.1MM, +26.8% vs. 4Q16, and 2017 revenue of $43.9MM, +13.2% vs. 2016.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.